

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 19

**Complete if Known**

Application Number	10/777,792
Filing Date	February 11, 2004
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Daniel E. Kolker
Attorney Docket Number	15270J-004766US

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	953	2008/0096818	04-24-2008	Schenk et al.	
	945	2008/0050367 A1	02-28-2008	Basi et al.	
	944	2007/0238154 A1	10-11-2007	Basi et al.	
	954	7,256,273	08-14-2007	Basi et al.,	
	955	2007/0161088	07-12-2007	Arumugham et al.	
	943	2007/0154480 A1	07-05-2007	Schenk et al.	
	956	2007/0134762	06-14-2007	Arumugham et al.	
	957	2007/0082367	04-12-2007	Godavarti et al.	
	946	2006/0280743 A1	12-14-2006	Basi et al.	
	958	2006/0257396	11-16-2006	Jacobsen	
	959	2006/0240486	10-26-2006	Johnson-Wood et al.	
	960	2006/0210557	09-21-2006	Luisi et al.	
	961	2006/0198851	09-07-2006	Basi et al.	
	962	2006/0193850	08-31-2006	Warne et al.	
	963	2006/0188512	08-24-2006	Yednock et al.	
	964	2006/0165682	07-27-2006	Basi et al.	
	965	2006/0160161	07-20-2006	Pavlikova et al.	
	966	2006/0153772	07-13-2006	Jacobsen	
	967	2006/0099206	05-11-2006	Sinacore	
	968	2006/0034858	02-16-2006	Schenk	
	969	2006/0029611	02-09-2006	Schenk	
	949	2005/0196399 A1	09-08-2005	Schenk et al.	
	970	2005/0191292	09-01-2005	Schenk	
	971	2005/0158304	07-21-2005	Schenk et al.	
	972	2005/0147613	07-07-2005	Raso	
	973	2005/0142132	06-30-2005	Schenk et al.	
	974	2005/0123544	06-09-2005	Schenk et al.	
	975	2005/0048049	03-03-2005	Schenk	
	976	2005/0019330	01-27-2005	Schenk	
	977	2005/0019328	01-27-2005	Schenk	
	978	2005/0013815	01-20-2005	Schenk	
	979	2004/0265308	12-30-2004	Schenk	
	980	2004/0265301	12-30-2004	Schenk et al.	
	981	2004/0247591	12-09-2004	Schenk et al.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **2** of **19****Complete if Known**

Application Number	10/777,792
Filing Date	February 11, 2004
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Daniel E. Kolker
Attorney Docket Number	15270J-004766US

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	982	2004/0247590	12-09-2004	Schenk et al.	
	983	2004/0219146	11-04-2004	Schenk	
	984	2004/0213800	10-28-2004	Seubert et al.	
	985	2004/0171816	09-02-2004	Schenk et al.	
	986	2004/0081657	04-29-2004	Schenk	
	906	6,339,068	01-15-2002	Krieg et al.	
	905	5,994,083	11-30-1999	Felici et al.	
	924	5,624,937	04-29-1997	Reel et al.	
	987	5,358,708	10-25-1994	Patel	
	951	5,262,332	11-16-1993	Selkoe	
	1084	4,879,213	11-07-1989	Fox et al.	

**U.S. APPLICATIONS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	988	12/106,206	04-18-2008	Schroeter	
	989	12/037,045	02-25-2008	Seubert	
	990	60/999,423	10-17-2007	Black	
	991	11/894,789	08-20-2007	Basi	
	992	11/894,754	08-20-2007		
	993	11/894,714	08-20-2007	Basi	
	994	11/894,665	08-20-2007	Schenk	
	995	11/893,123	08-20-2007		
	996	11/893,110	08-20-2007		
	997	11/893,103	08-20-2007		
	998	11/893,094	08-20-2007		
	999	11/842,120	08-20-2007	Schenk	
	1000	11/842,116	08-20-2007	Schenk	
	1001	11/842,113	08-20-2007	Schenk	
	1002	11/842,101	08-20-2007	Schenk	
	1003	11/842,056	08-20-2007	Basi	
	1004	11/842,042	08-20-2007	Basi	
	1005	11/842,023	08-20-2007	Basi	
	1006	11/841,993	08-20-2007	Arumugham	
Examiner Signature				Date Considered	

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/777,792	
			Filing Date	February 11, 2004	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Daniel E. Kolker	
Sheet	3	of	19	Attorney Docket Number	15270J-004766US

U.S. APPLICATIONS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1007	11/841,950	08-20-2007	Arumugham	
	1008	11/841,919	08-20-2007	Arumugham	
	1009	11/841,897	08-20-2007	Arumugham	
	1010	11/841,882	08-20-2007	Arumugham	
	1011	11/841,857	08-20-2007	Warne et al.	
	1012	11/841,849	08-20-2007	Arumugham	
	1013	11/841,794	08-20-2007	Warne et al.	
	1014	11/841,832	08-20-2007	Warne et al.	
	1015	60/793,014	04-18-2006	not named	
	1016	11/396,417	03-30-2006	Schenk	
	1017	11/396,391	03-30-2006	Schenk	
	1018	60/736,119	11-10-2005	Jacobson	
	1019	60/736,045	11-10-2005	Johnson-Wood	
	1020	60/735,687	11-10-2005	Jacobson	
	1021	60/691,821	06-17-2005	Godavarti	
	1022	09/980,568	03-12-2005	Hirtzer	
	1023	60/648,639	01-28-2005	Luisi et al.	
	1024	60/648,631	01-28-2005	Luisi et al.	
	1025	60/637,253	12-16-2004	Jacobson	
	1026	60/637,138	12-16-2004	Jacobson	
	1027	60/636,842	12-15-2004	Jacobson	
	1028	60/636,810	12-15-2004	Jacobson	
	1029	60/636,776	12-15-2004	Basi	
	1030	60/636,687	12-15-2004	Johnson-Wood	
	1031	60/636,684	12-15-2004	Basi	
	1032	60/622,525	10-26-2004	Pavliakova	
	1033	60/616,474	10-05-2004	Sinacore	
	1034	60/530,481	12-17-2003	Arumugham	
	1035	60/474,654	05-30-2003	Basi	
	1036	60/444,150	02-01-2003	Yednock	
	1037	09/979,701	03-13-2002	Schenk	
	1038	60/363,751	03-12-2002	Basi	
	948	60/251,892	12-06-2000	Basi et al.	
	1039	09/724,929	11-28-2000	Weiner	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/777,792
		Filing Date	February 11, 2004
		First Named Inventor	Schenk, Dale B.
		Art Unit	1649
		Examiner Name	Daniel E. Kolker
(Use as many sheets as necessary)		Attorney Docket Number	15270J-004766US
Sheet	4	of	19

U.S. APPLICATIONS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	1040	09/724,921		11-28-2000	Weiner	
	1041	09/724,575		11-28-2000	Schenk	
	1043	09/724,291		11-28-2000	Schenk	
	1044	09/724,288		11-28-2000	Schenk	
	1045	09/724,273		11-28-2000	Schenk	
	1050	09/723,765		11-28-2000	Schenk	
	1051	09/723,544		11-28-2000	Schenk	
	1052	09/724,495		11-27-2000	Schenk	
	1053	09/724,319		11-27-2000	Schenk	
	1054	09/723,766		11-27-2000	Hirtzer	
	1055	09/723,760		11-27-2000	Schenk	
	1056	09/723,725		11-27-2000	Hirtzer	
	1057	09/723,713		11-27-2000	Schenk	
	1058	09/585,656				
	1059	09/580,019		05-26-2000	Schenk	
	1060	09/580,015		05-26-2000	Schenk	
	1061	09/579,690		05-26-2000	Brayden	
	1062	09/497,553		02-03-2000	Schenk	
	1063	60/139,408		06-16-1999	Raso	
	1064	60/137,047		06-01-1999	Hirtzer	
	1065	60/137,010		06-01-1999	Schenk	
	1066	60/136,655		05-28-1999	Brayden	
	1067	09/322,289		05-28-1999	Schenk	
	1068	09/204,838		12-03-1998	Weiner	
	1069	60/925,228				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7 <sup>5</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	1070	EP	1 033 998	B1	10-19-2005			<input type="checkbox"/>
	921	EP	0 391 714	A2	10-10-1990			<input type="checkbox"/>
	1071	WO	06/083689	A2	08-10-2006			<input type="checkbox"/>
	1072	WO	06/081587	A2	08-03-2006			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/777,792
				Filing Date	February 11, 2004
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Daniel E. Kolker
(Use as many sheets as necessary)				Attorney Docket Number	15270J-004786US
Sheet	5	of	19		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†*
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	1077	WO	06/081587	A3	08-03-2006			<input type="checkbox"/>
	1073	WO	05/058941	A2	06-30-2005			<input type="checkbox"/>
	1074	WO	05/058940	A2	06-30-2005			<input type="checkbox"/>
	935	WO	04/080419	A3	09-23-2004			<input type="checkbox"/>
	918	WO	04/069182	A2	08-19-2004			<input type="checkbox"/>
	1078	WO	02/096457	A2	12-05-2002			<input type="checkbox"/>
	934	WO	02/46237	A3	06-13-2002			<input type="checkbox"/>
	772	WO	99/10008	A1	03-04-1999			<input type="checkbox"/>
	1079	WO	98/56418	A1	12-17-1998			<input type="checkbox"/>
	923	WO	95/23860	A2	09-08-1995			<input type="checkbox"/>
	922	WO	94/09364	A1	04-28-1994			<input type="checkbox"/>
	947	WO	92/22653	A1	12-23-1992			<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **6**of **12****Complete if Known**

Application Number	10/777,792
Filing Date	February 11, 2004
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Daniel E. Kolker
Attorney Docket Number	15270J-004766US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	927	AISEN, P., "Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Strategies," <i>Gerontology</i> , 43:143-149 (1997).	<input type="checkbox"/>
	912	AKIYAMA et al., "The amino-terminally truncated forms of amyloid $\beta$ -protein in brain macrophages in the ischemic lesions of Alzheimer's disease patients," <i>Neuroscience Letters</i> , 219:115-118 (1996).	<input type="checkbox"/>
	1047	ALBERTS et al., eds. <i>Molecular Biology of The Cell</i> , Third Edition, chapter 23, pages 1216-1218 (1994).	<input type="checkbox"/>
	773	ALBERTS ET AL., <i>Molecular Biology of the Cell</i> , 2nd Edition, pages 266-267, Garland Publishing Inc., New York (1989).	<input type="checkbox"/>
	790	BALES et al., "Administration of an Anti-A $\beta$ Fab Fragment to APP <sup>V717F</sup> Transgenic Mice Reduces Neuritic Plaque," Abstract P4-396, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based, <i>Neurology of Aging</i> , 25:S587 (2004).	<input type="checkbox"/>
	1048	BENDING, "Humanization of Rodent Monoclonal Antibodies by CDR Grafting," <i>A Companion to Methods in Enzymology</i> , 8:83-93 (1995).	<input type="checkbox"/>
	911	BEN-YEDIDIA et al., "Design of peptide and polypeptide vaccines," <i>Current Opinion in Biotechnology</i> , 8:442-448 (1997).	<input type="checkbox"/>
	915	BRITT et al., "Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice," <i>J. Infect. Dis.</i> , 171:18-25 Abstract (1995).	<input type="checkbox"/>
	1085	CASSET et al., "A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody By Rational Design," <i>Biochemical and Biophysical Research Communications</i> , 307:198-205 (2003).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/777,792	
			Filing Date	February 11, 2004	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Daniel E. Kolker	
			Attorney Docket Number	15270J-004766US	
Sheet	7	of	12		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
	932	CHAKRABARTI et al., "Vaccinia Virus Expression Vector: Coexpression of B-Galactosidase Provides Visual Screening of Recombinant Virus Plaques," <u>Molecular and Cellular Biology</u> , 5(12):3403-3409 (1985).	<input type="checkbox"/>	
	930	CHANG et al., "Adjuvant activity of incomplete Freund's adjuvant," <u>Advanced Drug Delivery Reviews</u> , 32:173-186 (1998).	<input type="checkbox"/>	
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561 (2003-2005).	<input type="checkbox"/>	
	1091	CLARK et al., <u>Chemical Immunology Antibody Engineering IgG Effector Mechanisms</u> , 65:88-110 (1997).	<input type="checkbox"/>	
	1046	COLMAN, "Effects of Amino Acid Sequence Changes On Antibody-Antigen Interactions," <u>Research In Immunology</u> , 145:33-36 (1994).	<input type="checkbox"/>	
	925	Colombian Patent Application No. 98071271, Technical Opinion of Jean Paul Vernot submitted on June 22, 2005 as evidence with the brief amending the nullity action (with English translation) (drafted November 2004).	<input type="checkbox"/>	
	908	COREY-BLOOM et al., "Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia," <u>J. Am. Geriatr. Soc.</u> , 41(1):31-37 Abstract (1993).	<input type="checkbox"/>	
	220	Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compsns. - comprise a macrocyclic lactone, a milbemydin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database (1997).	<input type="checkbox"/>	
	910	DREW et al., "Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide," <u>Journal of General Virology</u> , 73:2357-2366 (1992).	<input type="checkbox"/>	
	920	Ecuador Patent Application No. SP 98-2764, English translation of Expert Report submitted April 19, 2007 in support of the Appeal filed on July 29, 2005.	<input type="checkbox"/>	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/777,792		
		Filing Date	February 11, 2004		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1649		
		Examiner Name	Daniel E. Kolker		
Sheet	8	of	12	Attorney Docket Number	15270J-004766US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	942	European Examination Report of 03/09/2007 for European Application 01995364.5-1222.	<input type="checkbox"/>
	941	European Examination Report of 09/26/2007 for European Application 04720353.4-1222.	<input type="checkbox"/>
	940	European Examination Report of 10/08/2007 for European Application 01995364.5-1222.	<input type="checkbox"/>
	245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of $\beta$ -amyloid peptide is essential for modulation of fibrillar aggregation," <i>J. of Neuroimmunology</i> , 95:136-142 (1999).	<input type="checkbox"/>
	1081	GIBSON et al., "Abnormalities in Alzheimer's Disease Fibroblasts Bearing the APP670/671 Mutation," <i>Neurobiology of Aging</i> , 18(6):573-580 (1997).	<input type="checkbox"/>
	664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1988).	<input type="checkbox"/>
	931	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , page 98 (1988).	<input type="checkbox"/>
	1086	HOLMES et al., "Long-term Effects of A $\beta$ <sub>42</sub> Immunisation in Alzheimer's Disease: Follow-up of a Randomised, Placebo-controlled Phase I Trial," <i>Lancet</i> , 372: 216-223 (2008).	<input type="checkbox"/>
	1090	HOPP et al., "Prediction of protein antigenic determinants from amino acid sequences," <i>Proc. Natl. Acad. Sci. USA</i> 78:3824-3828 (1981).	<input type="checkbox"/>
	1092	HUSSAIN et al., "Selective Increases in Antibody Isotopes and Immunoglobulin G Subclass Responses to Secreted Antigens in Tuberculosis Patients and Healthy Household Contacts of the Patients," <i>Clinical and Diagnostic Laboratory Immunology</i> , 2(6): 726-732 (1995).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **9**

of

**12****Complete If Known**

Application Number	10/777,792
Filing Date	February 11, 2004
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Daniel E. Kolker
Attorney Docket Number	15270J-004766US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	1087	HYSLOP et al., "Will Anti-amyloid Therapies Work For Alzheimer's Disease?," <u>Lancet</u> , 372:180-182 (2008).	<input type="checkbox"/>	
	929	JANSEN et al., "Use of Highly Encapsulated <i>Streptococcus pneumoniae</i> Strains in a Flow-Cytometric Assay for Assessment of the Phagocytic Capacity of Serotype-Specific Antibodies," <u>Clinical &amp; Diagnostic Lab. Immunol.</u> , 5(5):703-710 (1998).	<input type="checkbox"/>	
	1049	MACCALLUM et al., "Antibody-antigen Interactions: <u>Contact Analysis and Binding Site Topography</u> , 262:732-745 (1996).	<input type="checkbox"/>	
	904	MAMIKONYAN et al., "Anti-A $\beta$ <sub>1-11</sub> Antibody Binds to Different $\beta$ -Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers," <u>J Biol Chem</u> , 282(31) 22376-22386 (2007).	<input type="checkbox"/>	
	913	MANNING et al., "Genetic Immunization with Adeno-Associated Virus Vectors Expressing Herpes Simplex Virus Type 2 Glycoproteins B and D," <u>Journal of Virology</u> , 71(10):7960-7962 (1997).	<input type="checkbox"/>	
	1082	MASLIAH et al., "Amyloid Protein Precursor Stimulates Excitatory Amino Acid Transport," <u>The Journal of Biological Chemistry</u> , 273(20):12548-12554 (1998).	<input type="checkbox"/>	
	1088	NASHAR et al., "Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes," <u>Vaccine</u> , 11(2):235-40 (1993), abstract only.	<input type="checkbox"/>	
	933	PCT International Preliminary Examination Report of 02/09/2004 for application PCT/US01/46587.	<input type="checkbox"/>	
	919	PCT Written Opinion of 12/14/04 for application PCT/US04/02856.	<input type="checkbox"/>	
	937	PCT International Preliminary Report on Patentability (Chapter I) of 09/16/2005 with Written Opinion of 05/09/2005 for application PCT/US04/007503.	<input type="checkbox"/>	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/777,792
				<i>Filing Date</i>	February 11, 2004
				<i>First Named Inventor</i>	Schenk, Dale B.
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Daniel E. Kolker
(Use as many sheets as necessary)				<i>Attorney Docket Number</i>	15270J-004766US
Sheet	10	of	12		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	1075	PCT International Preliminary Report on Patentability (Chapter II) of 12/21/2006 for application PCT/US2006/002837.		<input type="checkbox"/>
	1080	PCT International Preliminary Report on Patentability (Chapter I) of 07/31/2007 with Written Opinion for application PCT/US2006/004741.		<input type="checkbox"/>
	1076	PCT Written Opinion of 8/11/2006 for application PCT/US2006/002837.		<input type="checkbox"/>
	938	PCT International Preliminary Report on Patentability (Chapter II) of 04/27/2006 for application PCT/US04/007503.		<input type="checkbox"/>
	774	PEETERS et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <u>J. Immunological Methods</u> , 120:133-143 (1989).		<input type="checkbox"/>
	1042	PNAS Information for Authors (revised January 1997), Retrieved 21 April 2008 from <a href="http://web.archive.org/web/19970610092808/www.pnas.org/forauthors.html">http://web.archive.org/web/19970610092808/www.pnas.org/forauthors.html</a> .		<input type="checkbox"/>
	928	RAMMENSEE, H.G., "Chemistry of peptides associated with MHC class I and class II molecules," <u>Current Opinion in Immunology</u> , 7:85-96 (1995).		<input type="checkbox"/>
	926	RODRIGUEZ et al., "Enfermedad de Alzheimer. Situación Actual y Estrategias Terapéuticas" (Alzheimer Disease: present situation and therapeutic strategies), <u>Rev Cubana Med</u> [online], 38(2):134-142 (1999).		<input type="checkbox"/>
	1089	ROLPH et al., "Recombinant viruses as vaccines and immunological tools," <u>Immunity to Infection</u> , 9:517-521 (1997).		<input type="checkbox"/>
	856	SEUBERT et al., "Antibody Capture of Soluble A $\beta$ does not Reduce Cortical A $\beta$ Amyloidosis in the PDAPP Mouse," <u>Neurodegenerative Diseases</u> , 5:65-71 (2008).		<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/777,792	
			Filing Date	February 11, 2004	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Daniel E. Kolker	
Sheet	11	of	12	Attorney Docket Number	15270J-004766US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	1083	SMALL, " The Role of the Amyloid Protein Precursors (APP) in Alzheimer's Disease: Does the Normal Function of APP Explain the Topography of Neurodegeneration?," <u>Neurochemical Research</u> , 23(5):795-806 (1997).	<input type="checkbox"/>	
	186	SOLOMON et al., "Activity of monoclonal antibodies in prevention of In vitro aggregation of their antigens," <u>Immunotechnology</u> , 2(4):305 (1996).	<input type="checkbox"/>	
	950	SOLOMON et al., "Fast induction of anti- $\beta$ -amyloid peptide immune response," <u>Research and Practice in Alzheimer's Disease</u> , 6:260-264 (2002).	<input type="checkbox"/>	
	914	SPELLERBERG et al., "DNA Vaccines Against Lymphoma," <u>Journal of Immunology</u> , 159:1885-1892 (1997).	<input type="checkbox"/>	
	1093	STAUNTON et al., "Primary structures of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families," <u>Cell</u> 52(6):925-33 (1988), abstract only.	<input type="checkbox"/>	
	939	Supplementary Partial European Search Report of 04/10/2007 for European Application 04720353.4-1222.	<input type="checkbox"/>	
	907	TANG et al., "Genetic immunization is a simple method for eliciting an immune response," <u>Nature</u> , 356:152-154 (1992).	<input type="checkbox"/>	
	952	ULVESTAD et al., "Fc Receptors for IgG on Cultured Human Microglia Mediate Cytotoxicity and Phagocytosis of Antibody-coated Targets," <u>Journal of Neuropathology and Experimental Neurology</u> , 53(1):27-36 (1994).	<input type="checkbox"/>	
	775	VAN DEN DOBBELSTEEN et al., "Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14," <u>Scand. J. Immunol.</u> , 41:273-280 (1995).	<input type="checkbox"/>	
	936	VANDERSTICHELE et al., "Standardization of Measurement of B-amyloid(1-42) in Cerebrospinal Fluid and Plasma," <u>Int. J. Exp. Clin. Invest.</u> , 7(4):245-258 (2000).	<input type="checkbox"/>	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/777,792	
			Filing Date	February 11, 2004	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Daniel E. Kolker	
Sheet	12	of	12	Attorney Docket Number	15270J-004766US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	916	WINBLAD et al., "Hints of a therapeutic Vaccine for Alzheimer's?" <u>Neuron</u> , 38:517-519 (2003).	<input type="checkbox"/>	
	223	WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56 (1969).	<input type="checkbox"/>	
	909	XIANG et al., "Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines," <u>Immunity</u> , 2(2):129-135 Abstract (1995).	<input type="checkbox"/>	
	430	YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid $\beta$ -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).	<input type="checkbox"/>	
	917	YANKNER et al., "Neurotrophic and Neurotoxic effects of Amyloid $\beta$ Protein: Reversal by Tachykinin Neuropeptides," <u>Science</u> , 250:279-282 (1990).	<input type="checkbox"/>	
	793	ZAMEER et al., "Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid- $\beta$ : Potential Therapeutic for Alzheimer's Disease," Abstract P4-420, Page S593, presented at Poster Session P4:Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based, also <u>Neurobiology of Aging</u> , 25(Suppl. 2): p S593 (July 2004).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.